Dr. Richard Gordon, Ramapo Ophthalmology, Announces Participation in National Clinical Research Trial for treatment of Keratoconus and Corneal Ectasia

Top Quote Dr. Richard Gordon of Ramapo Ophthalmology provides AVEDRO, a Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System with VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes with Keratoconus or Corneal Ectasia after Refractive Surgery. End Quote
  • (1888PressRelease) May 09, 2013 - POMONA, NY - Ramapo Ophthalmology Associates is pleased to announce their participation in a national clinical research trial to examine an investigational treatment to stop or slow the progression of Keratoconus and Corneal Ectasia. The study, to be conducted by prominent Ophthalmologist Dr. Richard Gordon is open to participants who are 18 years of age or older who were diagnosed with Keratoconus or were diagnosed with Corneal Ectasia after they received refractive surgery (e.g. LASIK, PRK). Participants are required to make at least eight office visits over a 12- month period.

    The FDA approved cornea treatment study, which is sponsored by The American-European Congress of Ophthalmic Surgery (ACO) and Avedro Inc., is being conducted in 100 clinics in the U.S. The purpose is to study if this one-time treatment will strengthen the cornea so that the progress of Keratoconus and Corenal Ectasia is slowed or stopped. The treatment has been performed on thousands of patients in Japan and Europe.

    Dr. Gordon, a Keratoconus specialist, will use an ultraviolet-A illumination device (UVA light treatment), commonly known as KXL System, in combination with VibeXeye drops to treat the cornea.

    For more information about the cornea study and to schedule an appointment, please call Evelyn Bay at Ramapo Ophthalmology Associates at 845-362-1450 or email her at ebay ( @ ) ramapoeyecare dot com.

  • FB Icon Twitter Icon In-Icon
Contact Information